CorVel Competitors

Laboratory Co. of America (NYSE:LH) and CorVel (NASDAQ:CRVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Valuation and Earnings

This table compares Laboratory Co. of America and CorVel's gross revenue, earnings per share and valuation.

Laboratory Co. of America has higher revenue and earnings than CorVel.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Laboratory Co. of America and CorVel, as reported by MarketBeat.com.

Laboratory Co. of America presently has a consensus price target of $240.1429, suggesting a potential downside of 5.73%. Given Laboratory Co. of America's higher possible upside, research analysts plainly believe Laboratory Co. of America is more favorable than CorVel.

Profitability

This table compares Laboratory Co. of America and CorVel's net margins, return on equity and return on assets.

Insider & Institutional Ownership

89.3% of Laboratory Co. of America shares are held by institutional investors. Comparatively, 47.9% of CorVel shares are held by institutional investors. 0.7% of Laboratory Co. of America shares are held by company insiders. Comparatively, 50.4% of CorVel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Laboratory Co. of America has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Quest Diagnostics (NYSE:DGX) and CorVel (NASDAQ:CRVL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 47.9% of CorVel shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 50.4% of CorVel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Quest Diagnostics and CorVel's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Quest Diagnostics and CorVel, as provided by MarketBeat.

Quest Diagnostics currently has a consensus price target of $128.8750, suggesting a potential upside of 1.72%. Given Quest Diagnostics' higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than CorVel.

Risk & Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Quest Diagnostics and CorVel's revenue, earnings per share and valuation.

Quest Diagnostics has higher revenue and earnings than CorVel.

Summary

Quest Diagnostics beats CorVel on 7 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and DaVita (NYSE:DVA) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares CorVel and DaVita's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares CorVel and DaVita's top-line revenue, earnings per share (EPS) and valuation.

DaVita has higher revenue and earnings than CorVel.

Insider & Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 91.7% of DaVita shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 1.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CorVel and DaVita, as provided by MarketBeat.com.

DaVita has a consensus price target of $114.60, suggesting a potential upside of 5.14%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than CorVel.

Risk and Volatility

CorVel has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Summary

DaVita beats CorVel on 7 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and Amedisys (NASDAQ:AMED) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares CorVel and Amedisys' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares CorVel and Amedisys' top-line revenue, earnings per share (EPS) and valuation.

Amedisys has higher revenue and earnings than CorVel.

Insider & Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 85.9% of Amedisys shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 2.8% of Amedisys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

CorVel has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CorVel and Amedisys, as provided by MarketBeat.com.

Amedisys has a consensus price target of $274.4615, suggesting a potential downside of 3.05%. Given Amedisys' higher probable upside, analysts plainly believe Amedisys is more favorable than CorVel.

Summary

Amedisys beats CorVel on 10 of the 12 factors compared between the two stocks.

CorVel (NASDAQ:CRVL) and Chemed (NYSE:CHE) are both business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Insider and Institutional Ownership

47.9% of CorVel shares are owned by institutional investors. Comparatively, 86.0% of Chemed shares are owned by institutional investors. 50.4% of CorVel shares are owned by company insiders. Comparatively, 4.0% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for CorVel and Chemed, as provided by MarketBeat.

Chemed has a consensus target price of $580.00, suggesting a potential upside of 24.63%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than CorVel.

Profitability

This table compares CorVel and Chemed's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares CorVel and Chemed's top-line revenue, earnings per share (EPS) and valuation.

Chemed has higher revenue and earnings than CorVel.

Volatility and Risk

CorVel has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Summary

Chemed beats CorVel on 9 of the 12 factors compared between the two stocks.

R1 RCM (NASDAQ:RCM) and CorVel (NASDAQ:CRVL) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Earnings and Valuation

This table compares R1 RCM and CorVel's top-line revenue, earnings per share (EPS) and valuation.

CorVel has lower revenue, but higher earnings than R1 RCM.

Insider & Institutional Ownership

81.2% of R1 RCM shares are held by institutional investors. Comparatively, 47.9% of CorVel shares are held by institutional investors. 59.4% of R1 RCM shares are held by insiders. Comparatively, 50.4% of CorVel shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares R1 RCM and CorVel's net margins, return on equity and return on assets.

Risk & Volatility

R1 RCM has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, CorVel has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for R1 RCM and CorVel, as provided by MarketBeat.com.

R1 RCM presently has a consensus target price of $28.60, suggesting a potential upside of 12.51%. Given R1 RCM's higher probable upside, equities research analysts plainly believe R1 RCM is more favorable than CorVel.

Summary

R1 RCM beats CorVel on 9 of the 12 factors compared between the two stocks.